McKesson (MCK)
(Delayed Data from NYSE)
$525.28 USD
-0.66 (-0.13%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $525.55 +0.27 (0.05%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$525.28 USD
-0.66 (-0.13%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $525.55 +0.27 (0.05%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
Zacks News
S&P 500 Up 1000 Points in a Month: 10 Stocks Boosted the ETF
by Sanghamitra Saha
The S&P 500 touched the 3,300 mark on Jan 16, having added 1000 points in less than a month. Which stocks led to the ETF rally.
10 Top-Ranked S&P 500 Stocks Outperforming in 2020
by Sweta Killa
The rally has been broad based and there are winners across various corners of the space.
Is McKesson (MCK) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
The Zacks Analyst Blog Highlights: Estee Lauder, Bank of New York ??? Mellon, Canadian Pacific Railway, McKesson and Ameriprise Financial
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Estee Lauder, Bank of New York ??? Mellon, Canadian Pacific Railway, McKesson and Ameriprise Financial
Top Stock Reports for Estee Lauder, BNY Mellon & Canadian Pacific Railway
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Estee Lauder (EL), Bank of New York Mellon (BK) and Canadian Pacific Railway (CP).
MCK vs. ALGN: Which Stock Is the Better Value Option?
by Zacks Equity Research
MCK vs. ALGN: Which Stock Is the Better Value Option?
McKesson, Walgreens Form JV for European Pharmaceutical Unit
by Zacks Equity Research
The VA selects McKesson (MCK) as their prime pharmaceutical supplier.
SaMD Drives All Facets of US Healthcare: 3 Stocks to Watch
by Sreyoshi Mukherjee
As IoT slowly takes over the healthcare fraternity, let's take a look at three stocks which might prove to be profitable investment options over the long run.
Fed Reportedly Opens Criminal Investigation on Opioid Makers
by Kinjel Shah
Shares of some manufacturers and distributors of opioid drugs decline on Tuesday following reports that a criminal probe has been initiated by federal prosecutors.
Here's Why You Should Retain McKesson (MCK) Stock for Now
by Zacks Equity Research
McKesson (MCK) is gaining from strong segmental performance and solid prospects in the pharmaceutical and medical supplies distribution market. However, rising pricing pressure remains a concern.
McKesson (MCK) Q2 Earnings Meet Estimates, Revenues Beat
by Zacks Equity Research
McKesson's (MCK) Q2 results gain from higher revenues and solid show by U.S. Pharmaceutical and Specialty, and Medical-Surgical Solutions.
McKesson (MCK) Q2 Earnings Meet Estimates
by Zacks Equity Research
McKesson (MCK) delivered earnings and revenue surprises of 0.00% and 4.88%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Medical Products' Oct 30 Earnings Roster: MCK, MASI & More
by Zacks Equity Research
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have driven the performance of the players in the medical products space this earnings season.
Is McKesson (MCK) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
ResMed's (RMD) Q1 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
ResMed (RMD) registers growth at CER across its key operating segments in Q1.
Integra LifeSciences' (IART) Earnings Top Estimates in Q3
by Zacks Equity Research
We are upbeat about the year-over-year revenue growth in Integra LifeSciences' (IART) Codman Specialty Surgical segment.
New Strong Buy Stocks for October 25th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday:
Edwards Lifesciences (EW) Beats on Q3 Earnings, Ups EPS View
by Zacks Equity Research
Edwards Lifesciences (EW) reports strong Q3 sales on the recent FDA indication expansion of SAPIEN 3 and SAPIEN 3 Ultra systems.
Varian (VAR) Earnings and Revenues Surpass Estimates in Q4
by Zacks Equity Research
Varian (VAR) gains from core Oncology segment's solid contribution in fiscal Q4.
McKesson (MCK) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
McKesson's (MCK) Pharmaceutical and Specialty Solutions unit is expected to have driven its fiscal Q2 results.
Align Technology (ALGN) Beats on Q3 Earnings, Margins Fall
by Zacks Equity Research
We are upbeat about Align Technology (ALGN) witnessing continued momentum in Invisalign volumes across all geographies
Boston Scientific (BSX) Beats on Q3 Earnings, Tapers EPS View
by Zacks Equity Research
Boston Scientific (BSX) is making an all-out effort to solidify its core businesses and invest in the new technologies as well as the global markets. This reflects on the sales uptick in Q3.
Thermo Fisher (TMO) Beats on Q3 Earnings, Lifts Guidance
by Zacks Equity Research
We are encouraged that three out of Thermo Fisher's (TMO) four business segments have registered strong year-over-year revenue growth in Q3.
Quest Diagnostics (DGX) Q3 Earnings Surpass, View Strong
by Zacks Equity Research
We are upbeat about Quest Diagnostics' (DGX) expanded network access, which assists the company to accelerate volume growth in Q3.
Cerner's (CERN) AbleVets Buyout to Boost Federal Services
by Zacks Equity Research
Cerner (CERN) expects to close the AbleVets deal in the fourth quarter of 2019.